<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020730</url>
  </required_header>
  <id_info>
    <org_study_id>PTM-001-01</org_study_id>
    <nct_id>NCT05020730</nct_id>
  </id_info>
  <brief_title>Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa</brief_title>
  <official_title>A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial With a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenicis Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phoenicis Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study PTM-001-01 is a 12-week, randomized, placebo controlled, double blind study with a 12&#xD;
      week open-label extension to examine the immunomodulatory activity of PTM-001 in participants&#xD;
      with Hidradenitis Suppurativa (HS). Participants will be randomized to receive PTM-001 (400&#xD;
      mg) or matching placebo every day for 12 weeks after which all participants will receive&#xD;
      open-label PTM-001 400 mg daily for an additional 12 weeks. Randomization will be stratified&#xD;
      by Hurley Stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to receive PTM-001 (400 mg) or matching placebo every day for 12 weeks after which all patients will receive open-label PTM-001 400 mg daily for an additional 12 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of PTM-001 on IL-1β protein levels in lesional skin biopsies</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate a change in IL-1⍺, IL-23p19, IL-17A, IL-5, IL-6, TNF⍺, HBD-2 protein levels in lesional skin biopsies</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrate a change in IL-1β, IL-1⍺, IL-23p19, IL-17A, IL-5, IL-6, TNF⍺, HBD-2 mRNA expression in lesional skin biopsies</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrate a change in IL-1β, IL-1⍺, IL-23p19, IL-17A, IL-5, IL-6, TNF⍺, HBD-2 protein levels in serum</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrate a change in serum amyloid A levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain, as measured using a 10-point numerical rating scale, 1 through 10, with 10 being the worst.</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life using Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status using the Hurley Staging</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status using the International Hidradenitis Suppurative Severity Score System (IHS4)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status using the Hidradenitis Suppurative Clinical Response (HiSCR)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status using the Hidradenitis Suppurative Physician Global Assessment (HS-PGA)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status using the Hidradenitis Suppurative Area and Severity Index-Revised (HASI-R)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in abscesses and inflammatory nodules count (AN count)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>PTM-001 400 mg daily for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo daily for 12 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM-001</intervention_name>
    <description>PTM-001 (400 mg) every day for 12 weeks</description>
    <arm_group_label>PTM-001 400 mg daily for 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo every day for 12 weeks</description>
    <arm_group_label>Placebo daily for 12 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Had onset of symptoms consistent with HS at least 6 months prior to Screening.&#xD;
&#xD;
          -  Has had active HS for at least 2 months.&#xD;
&#xD;
          -  Has ≥ 5 HS abscesses or inflammatory nodules at Screening.&#xD;
&#xD;
          -  Agrees to maintain baseline wound care and antibiotic therapy, including oral&#xD;
             antibiotics, for the duration of the trial.&#xD;
&#xD;
          -  Agrees to use contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has other skin disease or condition that can interfere with HS assessment.&#xD;
&#xD;
          -  Has a positive test for TB, HIV, hepatitis B and/or hepatitis C at Screening.&#xD;
&#xD;
          -  Has a history of retinopathy or known clinically significant cardiovascular or&#xD;
             hematologic conditions.&#xD;
&#xD;
          -  Has taken any biologic drug within 3 serum half-lives. A list of potential biologics&#xD;
             and their half-lives&#xD;
&#xD;
          -  Has started oral antibiotics within 28 days of Study Day 1.&#xD;
&#xD;
          -  Has, within 2 weeks prior to Day 1, received a medication prohibited based on&#xD;
             cytochrome P450 (CYP3A4) interaction&#xD;
&#xD;
          -  Has such extensive disease that, in the opinion of the Investigator, it is difficult&#xD;
             to discriminate between active lesions and scarring.&#xD;
&#xD;
          -  Has more than 15 active tunnels at Screening.&#xD;
&#xD;
          -  Is pregnant, nursing or considering becoming pregnant.&#xD;
&#xD;
          -  Has a history of malignancy except non-melanoma skin cancer or cervical carcinoma in&#xD;
             situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ramsey Johnson, MSM</last_name>
    <phone>978-726-1478</phone>
    <email>ramsey@phoenicistx.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hidradenitis Suppurativa</keyword>
  <keyword>HS</keyword>
  <keyword>Inflammatory skin disease</keyword>
  <keyword>Humira</keyword>
  <keyword>P2X7</keyword>
  <keyword>IL-1β</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

